Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

Vanderbilt University Medical Center

Status and phase: Completed; Phase 2

Conditions: Pulmonary Artery Hypertension

Treatments: Device: Usual Care; Device: mHealth Intervention; Drug: Metformin; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03617458

180198

Details and patient eligibility

About

The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health Organization (WHO) functional class in humans with pulmonary artery hypertension (PAH).

Full description

The investigators propose to test the hypothesis that interventions to improve insulin resistance will improve exercise capacity and World Health Organization (WHO) functional class in PAH. The investigators propose three specific aims to test this 1) A prospective 2x2 factorial design 12-week clinical trial of metformin or placebo and activity intervention or usual care to assess effect on six minute walk and WHO functional class, 2) Assessment of the interventions in Aim 1 in a subset of patients on right ventricle (RV) and peripheral muscle function and lipid content and markers of pulmonary vascular disease to define how these interventions may work in PAH and 3) Identify and prospectively test peripheral blood markers of metformin response in PAH. The broad goals of this work are to demonstrate the efficacy and mechanisms of interventions against insulin resistance in PAH and to identify which patients are most likely to benefit from these interventions, moving to precision medicine in PAH.

The investigators are planning a factorial design trial. Patients will be randomized twice. The first is metformin or placebo and is quadruple randomized. The second is mobile health (mHealth) intervention via texts or standard of care and is not blinded to the patients, but is to the investigator and thus is triple randomized.

Enrollment: 73 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:• Adults aged 18 or older.

• Diagnosed with idiopathic, heritable, or drug- or toxin-associated pulmonary arterial hypertension (PAH) according to World Health Organization consensus recommendations.
• Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.
• Subjects must own a Bluetooth capable modern smartphone capable of receiving and sending text messages and an active data plan.
• WHO Functional Class I-III
• Ambulatory

Exclusion Criteria:

• Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity
• Pregnancy
• Diagnosis of PAH etiology other than idiopathic, heritable, or associated with drugs or toxins
• FEV1> or = 65% predicted AND normal chest imaging
• WHO Functional class IV heart failure
• Requirement of > 1 diuretic adjustment in the prior 30 days
• Preferred form of activity is not measured by an activity tracker (swimming, ice skating, stair master, or activities on wheels such as bicycling or rollerblading)
• Type I diabetes mellitus
• Prior diagnosis of cirrhosis
• Untreated hypo- or hyper-thyroidism
• estimated glomerular filtration rate (eGFR) by modification of diet in renal disease (MDRD) <60 milliliters per minute (mL/min)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Triple Blind

---

73 participants in 4 patient groups, including a placebo group

Metformin + mHealth Intervention

Active Comparator group

Description:

Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue. Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg by mouth (po) three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total).

Treatment:

Drug: Metformin

Device: mHealth Intervention

Placebo + Usual Care

Placebo Comparator group

Description:

Patient will receive non active medicine and routine medical care.

Treatment:

Drug: Placebo

Device: Usual Care

Metformin + Usual Care

Active Comparator group

Description:

Patient will receive active ingredient medicine with routine medical care. Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total).

Treatment:

Drug: Metformin

Device: Usual Care

Placebo + mHealth Intervention

Placebo Comparator group

Description:

Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.

Treatment:

Drug: Placebo

Device: mHealth Intervention